Gefitinib is a first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) and is the first TKI drugs permitted by the FDA for the treatment of patients with advanced NSCLC [4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.